Get the Stockscreener App
4.68
1.47%
-0.07
After Hours:
4.68
Cingulate Inc stock is traded at $4.68, with a volume of 270.59K.
It is down -1.47% in the last 24 hours and up +17.29% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.75
Open:
$4.75
24h Volume:
270.59K
Relative Volume:
1.58
Market Cap:
$33.62M
Revenue:
-
Net Income/Loss:
$-21.21M
P/E Ratio:
-0.1436
EPS:
-32.6
Net Cash Flow:
$-16.86M
1W Performance:
+11.43%
1M Performance:
+17.29%
6M Performance:
+9.35%
1Y Performance:
-5.84%
1-Day Range:
$4.50
$4.98
1-Week Range:
$4.10
$4.98
52-Week Range:
$3.20
$6.01
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.68 | 34.12M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
2026 world cup tactical analysis update: Will Cingulate Inc. stock maintain dividend yield2026 world cup usa national team group stage defensive leaders transition play knockout prediction tactical review - Улправда
Cingulate CEO cleared of charges, retains board confidence - MSN
Can Cingulate Inc stock weather global recessionQuarterly Profit Review & Growth Focused Entry Point Reports - moha.gov.vn
Cingulate continues stock-for-debt exchanges to reduce liabilities - TipRanks
Cingulate Inc Equity Warrant Stock Analysis and ForecastMarket Rumors and News & Low Risk Investment Tips - earlytimes.in
Trend Review: Is Cingulate Inc Equity Warrant stock affected by interest rate hikes2025 Big Picture & Low Drawdown Trading Techniques - moha.gov.vn
What technical charts say about Cingulate Inc. Equity Warrant stockMACD Histogram Signals & Minimize Portfolio Damage with Warnings - bollywoodhelpline.com
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Why Cingulate Inc stock remains a top recommendation2025 Market Trends & Step-by-Step Trade Execution Guides - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsMarket Insider Reports & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Will Cingulate Inc. stock maintain dividend yield2025 Earnings Impact & Risk Adjusted Buy and Sell Alerts - Улправда
Jobs Data: How analysts rate Cingulate Inc. Equity Warrant stock today2025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
How currency fluctuations impact Cingulate Inc. Equity Warrant stock2025 Earnings Surprises & Weekly Top Gainers Trade List - Улправда
Can Cingulate Inc. stock continue upward trendTrade Risk Assessment & Risk Adjusted Buy and Sell Alerts - Улправда
How analysts rate Cingulate Inc. Equity Warrant stock today2025 Market Overview & Long-Term Investment Growth Plans - Улправда
Bank Watch: Can Cingulate Inc. Equity Warrant stock hit record highs againJuly 2025 Fed Impact & Weekly Market Pulse Alerts - Улправда
Can Cingulate Inc. Equity Warrant stock hit record highs againJuly 2025 EndofMonth & Momentum Based Trading Ideas - Улправда
Cingulate (CING) Stock Price, Quote, News & History - Benzinga
What sentiment indicators say about Cingulate Inc. Equity Warrant stockTrade Signal Summary & Free Real-Time Volume Trigger Notifications - bolumsonucanavari.com
Is Cingulate Inc. Equity Warrant stock affected by interest rate hikesWeekly Market Report & Weekly Return Optimization Alerts - DonanımHaber
How rising interest rates impact Cingulate Inc. Equity Warrant stockWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Will Cingulate Inc. stock continue dividend increasesWeekly Stock Report & Weekly High Conviction Ideas - Улправда
Will Cingulate Inc. Equity Warrant stock maintain dividend yieldMarket Trend Summary & High Conviction Buy Zone Picks - Улправда
What analyst consensus says on Cingulate Inc. stock2025 Volatility Report & AI Enhanced Trading Alerts - DonanımHaber
Will Cingulate Inc. Equity Warrant stock benefit from upcoming earnings reportsTrade Ideas & Expert Approved Momentum Ideas - Улправда
Aug Breakouts: Will Cingulate Inc. stock return to pre crisis levels2025 Historical Comparison & Fast Moving Trade Plans - Улправда
How Cingulate Inc. stock performs in weak economyInsider Selling & High Accuracy Investment Signals - Улправда
Will Cingulate Inc. stock gain from lower inflationJuly 2025 Spike Watch & Reliable Breakout Forecasts - Улправда
Cingulate restores founder as CEO following concluded domestic battery case - The Business Journals
Cingulate Inc Reinstates Shane Schaffer as CEO - The Globe and Mail
Shane Schaffer reinstated as CEO of Cingulate - marketscreener.com
Cingulate reinstates Shane Schaffer as CEO, updates employment terms By Investing.com - Investing.com Canada
Cingulate reinstates Shane Schaffer as CEO, updates employment terms - Investing.com
Cingulate Inc. Announces Chief Executive Officer Changes, Effective December 15, 2025 - marketscreener.com
Cingulate presents Phase 3 results for CTx-1301, met primary endpoint - MSN
Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year - MSN
Cingulate Inc. Reports Q3 2025 Financial Results - MSN
Can Cingulate Inc. Equity Warrant stock deliver surprise earnings beatMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Will Cingulate Inc. stock attract more institutional investorsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
How strong is Cingulate Inc. stock balance sheetCEO Change & Accurate Intraday Trade Tips - Newser
Cingulate Inc. (NASDAQ:CING) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Dhanvantri Jeevan Rekha Limiteds Balance Sheet Supports LongTerm GrowthPrice Support Zones & Superior Wealth Building - earlytimes.in
Cingulate Inc Stock Analysis and ForecastEnergy Sector Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Sentiment Recap: Will Cingulate Inc. stock gain from lower inflation2025 Major Catalysts & High Accuracy Swing Entry Alerts - moha.gov.vn
Who’s Hired? Alvotech Promotes McClellan To COO - Citeline News & Insights
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):